Ampersand Capital Partners Makes Majority Investment in Tjoapack

Tjoapack Acquires Pharma Packaging Solutions to Expand into the United States

October 21, 2021

Healthcare Services

Netherlands-based contract packager Tjoapack has acquired Clinton, Tennessee-based Pharma Packaging Solutions (PPS). The deal, funded by Ampersand Capital Partners (Tjoapack's PE backer), gives Tjoapack a major U.S. facility and cold-chain / supply‑chain capabilities to accelerate its global expansion in pharmaceutical packaging and related services.

Ampersand Capital Partners Acquires CurTec

July 21, 2025

Packaging

Ampersand Capital Partners has acquired CurTec Group B.V., a Netherlands-based manufacturer of high-performance plastic packaging for pharmaceutical and specialty chemical applications, from Bencis Capital Partners in partnership with CurTec management. The deal positions Ampersand to scale CurTec's U.S. footprint, accelerate product innovation, and expand capacity and commercial capabilities to serve pharma and specialty chemicals customers globally.

Ampersand Capital Partners Majority Recapitalizes New England Peptide

October 7, 2019

Biotechnology

Ampersand Capital Partners completed a majority recapitalization of New England Peptide to support the company's worldwide growth initiatives and expand its peptide synthesis capabilities. As part of the transaction, Dr. José de Chastonay was appointed Executive Chairman; founders Sam and Jennifer Massoni remain noted in the announcement.

Ampersand Capital Partners Majority Recapitalizes Julius Clinical Research

November 28, 2023

Healthcare Services

Ampersand Capital Partners has completed a majority recapitalization of Julius Clinical Research, a Zeist-based clinical CRO, to support geographic expansion and deepen the company's scientific and therapeutic expertise. The investment will help Julius grow its CRO services in CNS, renal, cardiometabolic and infectious disease areas and expand its footprint in Europe and North America.

Ampersand Capital Partners Makes Growth Investment in Vibalogics GmbH

May 29, 2019

Biotechnology

Ampersand Capital Partners has made a growth equity investment in Vibalogics GmbH, a German CDMO specializing in development and GMP manufacturing of complex viral products. The investment will fund expansion of Vibalogics' process development and manufacturing capabilities and support broader growth in the U.S. and European markets.

Ampersand Capital Partners Invests in Alliance Pharma

November 18, 2021

Healthcare Services

Ampersand Capital Partners has made a growth equity investment in Alliance Pharma, a Malvern, Pennsylvania–based bioanalytical CRO. The funding will support Alliance’s expansion of global reach, scientific capabilities, and operational capacity while founder Frank Li remains a significant shareholder.